Olema Pharmaceuticals Inc 2025年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period endedJune 30,2025OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from _______ to _______Commission File Number:001-39712 OLEMA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b‐2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒ Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‐2 of the Exchange Act). Yes☐No☒ As of August 7, 2025, the number of outstanding shares of the Registrant’s common stock was 68,634,329.This number does not include17,094,163shares of common stock issuable upon the exercise of pre-funded warrants (which are immediately exercisable at an exercise price of$0.0001 per share of common stock, subject to beneficial ownership limitations) (See Notes 2 and 12 to Registrant's condensed consolidatedfinancial statements). Table of Contents PART I-FINANCIAL INFORMATION PART I. FINANCIAL INFORMATIONItem 1. Financial Statements (unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive LossCondensed Consolidated Statements of Stockholders’ EquityCondensed Consolidated Statements of Cash FlowsNotes to Unaudited Condensed Consolidated Financial StatementsItem 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPART II. OTHER INFORMATIONItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales of Equity Securities and Use of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. Exhibits PART I – FINANCIAL INFORMATION Olema Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets(Unaudited)(Amounts in thousands, except for share amounts) Olema Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss(Unaudited)(Amounts in thousands, except for share and per share amounts) ¹ The amounts for the three and six months ended June 30, 2025 include a one-time milestone payment to Aurigene of $10million.The amount for the six months ended June 30, 2024 include a one-time milestone payment to Aurigene of $5million. ² The weighted average shares used to compute net loss per share, basic and diluted, include the effect from the pre-fundedwarrants. Olema Pharmaceuticals, Inc. Olema Pharmaceuticals, Inc. Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)(Amounts in thousands, except for share amounts) Olema Pharmaceuticals, Inc. Condensed Consolidated Statements of Cash Flows(unaudited)(Amounts in thousands) Olema Pharmaceuticals, Inc.Notes to Condensed Consolidated Financial Statements (Unaudited) 1.Nature of the Business and Basis of Presentation Olema Pharmaceuticals, Inc. (“Olema” or the “Company”) is a clinical-stage biopharmaceutical company focused onthe discovery, development, and commercialization of next-generation targeted therapies for breast cancer andbeyond. The Company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. The Company's wholly-owned, leadproduct candidate, palazestrant (OP-1250), is a novel, orally-available small molecule with dual activity as both acomplete estrogen receptor ("ER") antagonist ("CERAN") and selective